Paradigm Shift in the Management of Metabolic Diseases—Next-Generation Incretin Therapy
(2023) In Endocrinology (United States) 164(12).- Abstract
Recently impressive weight loss has been reported for novel incretin therapies based on dual-and triple-hormone receptor coagonists. These agents have potential as being positioned as early therapeutics for metabolic diseases for which weight loss is preferred, such as type 2 diabetes, obesity, cardiovascular diseases, and nonalcoholic liver disease. This development will change the landscape of future therapy and also place weight reduction at the centerpiece for therapy of metabolic diseases.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/26c3e0d0-ea8a-4197-ae7f-10ee0a0210ff
- author
- Ahrén, Bo LU
- organization
- publishing date
- 2023-12
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- coagonists, GIP, GLP-1, glucagon, obesity, type 2 diabetes
- in
- Endocrinology (United States)
- volume
- 164
- issue
- 12
- article number
- /bqad166
- publisher
- Oxford University Press
- external identifiers
-
- scopus:85178181698
- pmid:37951841
- ISSN
- 0013-7227
- DOI
- 10.1210/endocr/bqad166
- language
- English
- LU publication?
- yes
- id
- 26c3e0d0-ea8a-4197-ae7f-10ee0a0210ff
- date added to LUP
- 2023-12-18 14:31:27
- date last changed
- 2024-08-08 13:10:17
@article{26c3e0d0-ea8a-4197-ae7f-10ee0a0210ff, abstract = {{<p>Recently impressive weight loss has been reported for novel incretin therapies based on dual-and triple-hormone receptor coagonists. These agents have potential as being positioned as early therapeutics for metabolic diseases for which weight loss is preferred, such as type 2 diabetes, obesity, cardiovascular diseases, and nonalcoholic liver disease. This development will change the landscape of future therapy and also place weight reduction at the centerpiece for therapy of metabolic diseases.</p>}}, author = {{Ahrén, Bo}}, issn = {{0013-7227}}, keywords = {{coagonists; GIP; GLP-1; glucagon; obesity; type 2 diabetes}}, language = {{eng}}, number = {{12}}, publisher = {{Oxford University Press}}, series = {{Endocrinology (United States)}}, title = {{Paradigm Shift in the Management of Metabolic Diseases—Next-Generation Incretin Therapy}}, url = {{http://dx.doi.org/10.1210/endocr/bqad166}}, doi = {{10.1210/endocr/bqad166}}, volume = {{164}}, year = {{2023}}, }